Section Arrow
Quote
BNR.NASDAQ
- Burning Rock Biotech Limited
Quotes are at least 15-min delayed:2025/07/03 03:59 EDT
Last
 3.23
+0.03 (+0.94%)
Day High 
3.3182 
Prev. Close
3.2 
1-M High
4.19 
Volume 
4.79K 
Bid
--
Ask
--
Day Low
3.22 
Open
3.29 
1-M Low
2.8 
Market Cap 
34.45M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 3.4 
20-SMA 3.31 
50-SMA 3.02 
52-W High 7.9 
52-W Low 2.18 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-23.10/--
Enterprise Value
62.21M
Balance Sheet
Book Value Per Share
7.40
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
515.82M
Operating Revenue Per Share
7.50
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
NEOGNeogen Corp5.23+0.15+2.95%879PE
BIAFbioAffinity Technologies0.29+0.0265+10.06%-- 
DHRDanaher Corp202.5+1.4+0.70%38.97PE
OPKOPKO Health1.34+0.01+0.75%-- 
TMOThermo Fisher Scientific427.76+6.29+1.49%24.72PE
Quotes are at least 15-min delayed：2025/07/03 03:59 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.